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Reclassification of Neuroendocrine Tumors Improves the
Separation of Carcinoids and the Prediction of Survival
Birgit Guldhammer Skov, MD, DrMSci,* Mark Krasnik, MD,† Sylvie Lantuejoul, MD, PhD,‡
Torsten Skov, MD, PhD,§ and Elisabeth Brambilla, MD, PhD‡
Introduction: The classification of neuroendocrine lung tumors has
changed over the last decades. Reliable diagnoses are crucial for the
quality of clinical databases. The purpose of this study is to deter-
mine to which extent the use of different diagnostic criteria of
neuroendocrine lung tumors has influenced the classification of
these tumors. The prognostic information of tumor, node, metastasis
descriptors was also evaluated.
Methods: We retrieved 110 tumors from the period 1989 to 2007.
All tumors were reclassified according to the World Health Orga-
nization classification of 2004. Tumor, node, metastasis descriptors
were evaluated.
Results: By reclassification, the diagnoses on 48 tumors (44%) were
changed. More diagnoses were changed in the older part of the
material. A significantly different survival was shown for all patients
in relation to tumor size (p 0.0001). An endobronchial component
was seen in 54%, 31%, and 11% of typical carcinoid, atypical
carcinoid, and large cell neuroendocrine carcinoma, respectively
with no impact on survival (p  0.90). For all included patients the
survival was significantly worse for patients having metastasis to N1
nodes as compared with N0 (p  0.03). However, the number of
removed lymph nodes were insufficient for definitive determination
of the prognostic impact of node metastases. Regarding the revised
diagnoses, a significant difference in survival between typical car-
cinoid, atypical carcinoid, large cell neuroendocrine carcinoma and
small cell carcinoma was noted (p  0.005).
Conclusion: Tumors must be rediagnosed before entering a central
database. Tumor and node seem to be useful predictors of survival.
KeyWords: Neuroendocrine tumor, Classification, Size, Endobron-
chial, TNM, Survival.
(J Thorac Oncol. 2008;3: 1410–1415)
The classification of neuroendocrine lung tumors (NE tu-mor) has changed over the last decades.1–3 The present
World Health Organization (WHO) classification based on a
study by Travis et al.4 includes typical carcinoid (TC), atyp-
ical carcinoid (AC), large cell neuroendocrine carcinoma
(LCNEC), and small cell lung carcinoma (SCLC).
The tumor, node, metastasis (TNM) classification
has traditionally not been regarded as applicable to these
tumors and the value of TNM staging in relation to
survival of these patients is largely unknown. However,
new data including those from the retrospective Interna-
tional Association for the Study of Lung Cancer (IASLC)
database seem to show that the TNM classification may be
of value also for NE tumors.5–8
Excluding SCLC, NE tumors are rare, comprising less
than 5% of all malignant lung tumors. This precludes most
centers from making studies to elucidate the value of TNM
for these tumors. IASCL has taken the initiative to establish
a central, international database of NE tumors (excluding
SCLC which will probably be collected in a separate data-
base). A meeting regarding this was arranged at the Bromp-
ton Hospital, London in December 2007.
The retrospective part of the IASLC database poses a
special challenge because of the changes in the tumor clas-
sification. Consistent, reliable, and reproducible diagnoses
are crucial for the quality of the proposed database. The
purpose for this study is to determine to which extent the use
of different diagnostic criteria of NE tumors over the last 20
years has influenced the classification of these tumors. We
also wanted to determine if the revised diagnoses gave a
better separation of the diagnostic groups than the original
diagnoses in terms of survival. Finally we wanted to deter-
mine the significance of having an endobronchial tumor
component and the relation between tumor size, node status
and survival.
PATIENTS AND METHODS
One hundred ten surgically resected tumors originally
diagnosed as neuroendocrine tumors (excluding SCLC) and
coded as “carcinoid tumor” in the SNOMED system
(M82401) in the period 1989–2007 were retrieved from the
Pathology System, Department of Pathology, Gentofte, Den-
mark. As SNOMED coding of these tumors has not been
standardized, some LCNEC were coded as such (M80133) as
well as “carcinoid tumor” for which reason these tumors were
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retrieved. Two SCLC were coded as such (M80413) as well
as “carcinoid tumor” and were included.
The following parameters were registered from the
pathology reports and medical records: age, sex, date and
type of operation, presence or absence of an endobronchial
tumor component, tumor size, number of tumors in the
resection, number of N1 and N2 nodes removed and number
of nodes with metastases, stage, surgical treatment, adjuvant
therapy, and survival. An endobronchial tumor component
was defined as a tumor located endobronchially within large
bronchi having cartilaginous walls as opposed to peripheral
lesions defined as those in subpleural locations or in alveolar
parenchyma without any involvement of hilar or sizable
conducting or proximal bronchi on histologic examination.
Other T descriptors such as visceral pleura invasion and
partiel atelectasis were insufficiently reported and were not
registered.
As this study was retrospective we did not include
smoking history.
Follow-up information was obtained from the patient files
and from the Danish Death Certificate Register. This study was
not designed to answer questions regarding clinical symptoms,
pulmonary function, bronchoscopic features, computed tomog-
raphy, and positron emission tomography findings for which
reason such data were not registered.
The histologic rediagnosis was done on H&E stained
slides, no immunohistochemical staining was included. All
the cases were diagnosed according to the current WHO
classification of lung tumors9 (Table 1).
The inclusion period (1989–2007) was subdivided into
3 periods: (1) 1989–1998 as the study by Travis et al.4 on
which the current classification is based was published in
1998, (2) 1999–2004 as this classification was implemented
in the WHO classification of lung tumors from 1999,10 and
(3) 2005–2007 as the classification from 1999 was unchanged
in the current WHO classification.9
Mitoses were counted on an Olympus BX60 micro-
scope at an high power field magnification of 40x and a
standard field of view number of 20 (0.2 mm2). Mitoses were
counted in the most mitotically active areas; such areas were
identified by scanning the tumor at medium magnification.
The criteria favoring a mitosis over a pyknotic cell were:
absence of a nuclear membrane or a central clear zone,
presence of hairy rather than triangular projections and ba-
sofilia rather than eosinofilia of the cytoplasm.11 Only what
was appreciated as definite mitoses were counted as such.
All cases were reviewed by SL, BGS, and EB, who all
were blinded to the original diagnoses. The few discrepancies
were resolved by consensus evaluation by the pathologists.
One to ten slides per tumor were used for the revised
diagnoses.
Statistical analyses were performed using JMP version
6. 2 test and Kaplan-Meier (log-rank) were used, regarding
a p value of 0.05 or less as significant.
RESULTS
Included Material in Different Analyses
All the 110 retrieved, resected tumors were included in
the analyses regarding the relation between the original and
the revised diagnoses. For analysis of survival by original
diagnosis five cases were excluded (one NE hyperplasia, two
NSCLC  tumorlet, one NSCLC  TC and one patient had
missing survival data). For analyses regarding revised tumor
type in relation to age, sex, tumor size, endobronchial com-
ponent, node status, and survival we had 100 NE tumors as 10
tumors were excluded for the following reasons: One case
originally diagnosed as a LCNEC was revised as a pulmonary
blastoma, which is not a NE tumor. Two cases were excluded
because there was no NE tumor at the rediagnosis (one case
with a tumorlet and one cases with NE cell hyperplasia i.e.,
neuroendorcrine proliferations measuring less than 5 mm), 3
cases were excluded because they had a NSCLC as well in
the resection (two cases with NSCLC  foci of tumorlet and
one case with NSCLC  TC), and one case was excluded
because the material was crushed and unfit for diagnosis.
Lastly, three cases were excluded as they were reclassified as
“carcinoid not otherwise specified” due to the material being
too small for further classification into TC and AC.
Original and Revised Diagnoses
The number of tumors in each tumor category accord-
ing to the original and the revised diagnoses are shown in
Table 2. Sixty-two cases (56%) were classified to the same
category on both occasions whereas 48 cases (44%) were
revised to another diagnosis. Most of the revised diagnoses
were made on cases originally diagnosed as “carcinoid NOS”
and “malignant carcinoid.” Twenty-six resections originally
diagnosed as carcinoid NOS were revised to 19 TC, 3 AC,
and 1 case not diagnostic; in 3 cases the material was too
small for further subclassification into TC or AC. As the
category “malignant carcinoid” does not exist in the current
TABLE 1. WHO Criteria for the Diagnosis of NE Tumors
Histological Features TC AC LCNEC SCLC
Organoid pattern Yes Yes Yes Yes
Mitosis 2/2 mm2 2–10/2 mm2 10/2 mm2 10/2 mm2
Necrosis None /  
N/C Moderate Moderate Low High
Nucleoli Occasional Common Very common Absent (or inconspicuous)
Nuclear chromatin Finely granular Finely granular Usually vesicular Finely granular
TC, typical carcinoid; AC, atypical carcinoid; LCNEC, large cell neuroendocrine carcinoma; SCLC, small cell carcinoma; NE tumor,
neuroendocrine lung tumor; WHO, World Health Organization; N/C, Nuclear/cytoplasmic ratio.
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WHO classification all eight of these tumors were revised,
five moved to AC, two to LCNEC and one to SCLC.
Fourteen percent (5 of 35 cases) of tumors diagnosed in
the first period (1987–1998) were classified into the same
category by the original and the revised diagnoses. In the
second (1999–2004) and third periods (2005–2007) these
numbers were 76% (39 of 51 cases) and 88%, (21 of 24
cases), respectively. The three cases classified to different
categories in the last period included two LCNEC reclassified
to SCLC and one TC reclassified to AC.
Revised Diagnoses and Impact on Pathologic
and Clinical Features Including Survival
The clinical features for the included 100 patients are
summarized in Table 3. Patients with TC tended to be 8–10
years younger than patients with AC, LCNEC, and SCLC.
The youngest patient with TC was 15 years old and the oldest
83, and for TC the range for age was greater than for the other
categories. TC and AC were more common in females than in
males, whereas LCNEC and SCLC were more common in
males. An endobronchial component was seen in 54%, 31%,
and 11% of TC, AC, and LCNEC, respectively with no
difference in the number in relation to sex in either tumor
type. There was no association between the presence of an
endobronchial component and survival for the whole material
(p  0.90).
The median tumor size for TC, AC, LCNEC, and
SCLC was 25 mm, 25 mm, 41 mm and 30 mm, respec-
tively. For TC, 20 tumors (42%) were 20 mm or smaller,
14 (29%) were 21 to 30 mm, 11 (23%) were 31 to 50 mm
and only 2 (4%) were greater than 50 mm. For one TC we
had no measure. The same numbers for AC were 3 (19%),
7 (44%), 3 (19%), 2 (12%) and 0, respectively. For one AC
we had no measure. All patients had only one tumor in the
resection. A significantly different survival was shown for
all patients in relation to tumor size (p  0.0001, log-rank
for trend) (Figure 1).
Due to the low number of deaths of in each of the
diagnostic groups the survival in relation to size could not be
further analyzed by diagnostic group. Three (6%) of patients
with TC were N1 node positive and 2 (4%) were N2 positive
(station 5 and 7 respectively) and both were also N1 positive
and one of these had an endobronchial component. For AC 4
patients (25%) were N1 positive and 4 were N2 positive (1
patient in station 6 and 3 in station 7). Eleven patients (25%)
with TC and 4 patients (25%) with AC had no N1 nodes
removed; the corresponding numbers for N2 nodes were 25
TABLE 2. Original and Revised Diagnosis for 110 Cases
Original Diagnosis
Revised Diagnosis
TC AC LCNEC incl. comb. SCLC incl. comb. Carcinoid NOS Other
TC 33 27 4 0 1 0 1a
AC 6 2 4 0 0 0 0
LCNEC incl. comb. 31 0 0 25 5 0 1b
SCLC incl. comb. 2 0 0 0 2 0 0
Malignant carcinoid 8 0 5 2 1 0 0
Carcinoid NOS 26 19 3 0 0 3 1c
Other 4 0 0 0 0 4
NE hyperplasia 1d
NSCLC  tumorlet 2e
NSCLC  TC 1f
N 110 48 16 27 9 3 7
a Tumorlet.
b Blastoma.
c Chrushed, non-diagnostic material.
d NE hyperplasia.
e NSCLC  tumorlet.
f NSCLC  TC.
TC, typical carcinoid; AC, atypical carcinoid; LCNEC, large cell neuroendocrine carcinoma; SCLC, small cell carcinoma; NOS, not otherwise
specified; NA, no data available; NE, neuroendocrine lung.
TABLE 3. Patients Characteristics
No. of Patients TC AC LCNEC SCLC
Gender (F/M) 30/18 9/7 11/16 1/8
Age in year
(median/
range)
55 (15–83) 64 (42–73) 65 (31–79) 63 (42–72)
Endobronchial
component
(N/%)
26 (54) 5 (31) 3 (11) 0 (0)
Stage
IA  IB 43 9 15 2
IIA  IIB 1 2 3 2
IIIA  IIIB 2 3 7 3
IV 0 1 0 0
NA 2 1 2 2
N1 node positive
(N/%)
3 (6) 4 (25) 6 (22) 2 (22)
N2 node positive
(N/%)
2 (4) 4 (25) 4 (14) 3 (33)
TC, typical carcinoid; AC, atypical carcinoid; LCNEC, large cell neuroendocrine
carcinoma; SCLC, small cell carcinoma; NA, no data available.
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(52%) for TC and 9 (56%) for AC. For all included patients
the survival was significantly worse for patients having me-
tastasis to N1 nodes (n  15) as compared with N0 (p 
0.03). For metastases to N2 nodes (n  13) we could not
demonstrate a similar relation (p  0.39).
Forty-three (90%) of patients with TC were in stage
I as where 38% of patients with AC. One patient (2%) and
2 patients (13%) with TC and AC respectively were in
stage II. One patient with AC was diagnosed in advanced
stage (stage IV).
Median follow-up was 4.4.years (range, 0.5–18 years).
Nineteen patients were dead at the time of the end of this
study. Survival curves according to the original and the
revised diagnoses are shown in Figure 2. In both classifica-
tions patients with TC had the best survival. Carcinoid NOS
(primarily a mixture of TC and AC) had an intermediate
survival according to the original diagnoses while the curves
for the other diagnoses were more or less alike telling us that
this classification was unable to separate the different tumor
groups in relation to survival. However, with the revised
diagnoses, all 4 major diagnosis groups split very nicely with
a p value 0.005 showing the best survival for TC, an
intermediate survival for patients having AC, and poorest
survival for LCNEC and SCLC.
DISCUSSION
In this study we demonstrated that about half of NE
tumors diagnosed in the last two decades at the Department of
Pathology, Gentofte, Denmark would have been classified to
a different diagnostic group, had the present WHO classifi-
cation been used. This has great impact on the archive
tumors, which are to be included in the purposed IASLC NE
tumor database. Certainly all these tumor must be reassessed.
Furthermore we demonstrated that the current WHO
classification of lung tumors9 separates NE tumors in four
separate groups with regard to survival as compared with old
classifications in which the survival curves for the different
tumor categories were overlapping. This is in accordance
with previous studies.4,12 Most of the reclassified cases were
originally diagnosed as carcinoid without distinction between
TC and AC or malignant carcinoid, a category which does not
exist in the current WHO classification. These finding are in
accordance with another study.13
The diagnostic accuracy improved significantly during
the more recent years especially after 1999 in which year the
current classification was published for the first time in the
WHO classification.10 Thus, as one might expect, standard-
ized diagnostic criteria for specific tumors improve the diag-
nostic accuracy among pathologists.
The distinction between TC and AC is based on the
number of mitoses and/or the presence/absence of necroses.9
Counting mitoses is time consuming and difficult. As recom-
mended, the mitoses were counted in the areas with highest
mitotic activity4 and if mitoses were scarce the whole section
was scanned for areas with mitotic figures. The thickness and
the fixation of the slides may influence the evaluated areas.
The distinction between pyknotic cells and mitoses can be
difficult and only what was appreciated as definite mitoses
were counted. The presence or absence of necrosis may also
be difficult as the necroses in AC often are small and
punctuated and the distinction between true coagulative and
“incipient” necrosis can be subtle. As the survival curves
separate TC and AC very well according to the revised
diagnoses it seems that we were able to classify the carcinoids
into meaningful categories. However, other methods for es-
timating the proliferative status of NE tumors especially TC
and AC e.g., the immunohistochemical staining for MIB1 (Ki
67) must be further evaluated to see if this method is able to
give diagnostic information on an equal or higher level than
the counting of mitoses. Biomarkers such as p16, cyclin D1
and Rb protein have been shown to be differentially ex-
pressed in low grade versus high grade NE tumor,14 but it
FIGURE 1. Survival according to tumor size (all subgroups
included) (data missing for eight patients: for seven the
tumor size were not reported and one had missing survival
data).
FIGURE 2. Survival according to original and revised diag-
noses (survival data missing for one TC).
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remains to be evaluated whether these may contribute to the
morphologic classification of these tumors.
All tumors were diagnoses within a time span of a few
weeks in order for the pathologists to benefit from having
access to many tumor samples at the same time; in the daily
practice most pathologists only see these tumors at rare
occasions. The pathologists in this study were experienced
lung pathologists with an interest in pulmonary NE tumors. In
cases with different diagnoses a consensus diagnosis was
found. These facts may also have contributed to the good
separation of the diagnostic groups.
The aim of this study was not to evaluate the interob-
server agreement which has been done previously. In one
study15 experienced lung pathologists achieved excellent re-
producibility (kappa values above 0.6) on 40 surgically re-
sected NE tumors. The reproducibility of these diagnoses was
determined in another study including one pathologist with
particular interest in lung pathology, one general pathologists
and one trainee.13 All nonrepresentative specimens with ne-
crosis or crush-artifacts were eliminated leaving 100 tumor
blocks (42 NSCLC, 27 TC, 3AC, 23 SCLC and 4 LCNEC)
for examination. In three of the NE tumors differences in the
diagnosis were observed. However, leaving out tumors with
necroses might have eliminated many AC and thus the
investigators might have eliminated one diagnostic pitfall
especially regarding TC and AC. Given the degree of diffi-
culty of diagnosing these rare tumors there will probably
always be some interobserver disagreement and at least a
subset of these tumors should probably be reviewed by a
panel of experienced pathologists before entering an interna-
tional databases.
In terms of survival the revised diagnoses separated the
NE tumors better than the original diagnoses. As seen in
previous studies TC and AC had the best prognosis and
SCLC had a poor prognosis.1,4 Especially the split of the
category “carcinoid NOS” primarily into TC and AC and the
revised diagnoses on the category “malignant carcinoid”
helped to separate the tumors in clear prognostic groups.
It could be questioned whether the observed prognostic
effect of tumor size is real or whether it reflects differences in
tumor composition. We have run a proportional hazards
model including the diagnosis as well as the tumor size.
Compared with the model with size alone, the estimate of the
effect of size changed only about 3%. Thus, there did not
seem to be any appreciable degree of confounding. Due to
low number of tumors and events in each category we were
unable to define the optimal split in tumor size in relation to
survival for the specific diagnoses. Larger studies are war-
ranted to answer the question regarding the prognostic impact
of tumor size on survival for the different tumor groups.
The number of tumors in each category was too small
to make any analyses within diagnostic subgroups of the
relation between TNM descriptors and survival. Metastases
to N1 nodes had a significant impact on survival for the whole
material. However, many patients had no nodes removed and
few patients had N1 (15 patients) or N2 (13 patients) metas-
tases. Thus, the N stage for a specific patient may not mirror
the real N status. The prognostic impact of N status has been
studied previously. Thomas et al.12 examined 23 TC and 11
AC with positive thoracic lymph nodes and found that pa-
tients with AC and N1 positive nodes had a high likelihood of
recurrent disease if treated with surgery alone and had a
significantly worse outcome compared with patients with TC
with N1 positive nodes. Others have found that the prognosis
in bronchial carcinoid tumors was more related to N status
than to histologic type with N2 being the most important
prognostic factor.16 A multicenter study reported a significant
difference in nodal involvement between TC and AC and this
had prognostic value,17 while Filosso et al. did not find a
prognostic impact of the nodal metastases in neither TC nor
AC.18 Previously, many centers have not paid attention to
radical lymphadenectomy in patients with TC and AC as
these tumors were regarded as benign. This might have
hampered the studies regarding the prognostic value of node
involvement in these tumors. Whether the N status for NE
tumors (primarily TC and AC) have the same prognostic
information as for NSCLC either alone or in combination
with other factors including endobronchial position of these
tumors, needs to be evaluated in the future studies.
We registered an endobronchial component in more
than half of the patients with TC and in 1/3 of patients with
AC. For all included patients an endobronchial component
was of no significance in relation to survival. However, the
number of patients in each category is small and further
validation of an endobronchial component in relation to
survival, especially for TC and AC, is warranted. These data
were mainly collected from the pathology reports and the
depth of the tumor growth was not measured for any of the
tumors. Neither had any of the patients had an high-resolution
computed tomography to determine intraluminal versus ex-
traluminal tumor growth. Cardillo et al.16 had 60% of 163
tumors localized centrally in the bronchial tree without sep-
arating these in TC and AC. In another Italian study 80% of
carcinoids were located in the bronchus.19 None of these
studies measured the depth of the tumor in the bronchial wall.
Whether this location may influence the prognosis either
alone or in combination with N status remains to be solved.
The same is true for the optimal treatment of carcinoids with
this location. Bronchoscopic treatment of endobronchial TC
seems to be a potential tissue-sparing alternative to surgical
resection20 especially in cases with primarily endobronchial
growth of TC and the existence of an endobronchial compo-
nent together with a measuring of the growth into the bron-
chial wall. None of the patients in the present study had had
a bronchoscopic treatment.
CONCLUSION
In this study we demonstrated that the different classi-
fications of NE-tumors during the last decade have great
impact on the diagnosis of a specific case. NE-tumors to be
included in clinical studies must be revised according to the
current WHO classification, and this is also true for tumors
entering the proposed IASLC database for NE tumors. As
these tumors are rare at least a subset of tumors should be
revised by an expert panel.
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The current classification is able to separate NE-tumors
in subgroups with distinctly different survival outlook and T
and N descriptors seem to be applicable for these tumors.
However, the impact on survival of tumor size, tumor loca-
tion including endobronchial component, N and M status and
recurrence remains to be further elucidated. For this purpose
the proposed IASLC database will be of great value.
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